Literature DB >> 11981723

Nosocomial infections in left ventricular assist device recipients.

Preeti N Malani1, David B S Dyke, Francis D Pagani, Carol E Chenoweth.   

Abstract

Infection remains a serious complication of left ventricular assist device (LVAD) implantation. We performed a cohort study to assess infections among patients who underwent LVAD implantation from October 1996 through May 1999. Thirty-six LVADs were implanted in 35 patients; the mean duration (+/- standard deviation) of LVAD use was 73+/-60 days (total for all patients, 2565 days). Sixteen patients developed surgical site infections (SSIs; rate, 6.2 infections per 1000 LVAD days); 9 were deep-tissue or organ/space infections and 7 were superficial. Other infections included 7 cases of pneumonia (rate, 2.7 cases per 1000 LVAD days), 6 venous infections (rate, 2.3 per 1000 LVAD days), 2 bloodstream infections (rate, cases 0.8 per 1000 LVAD days), 3 urinary tract infections, and 2 skin and soft-tissue infections. Deep SSIs were associated with the requirement for postoperative hemodialysis (P=.02). Overall use of antibiotics was extensive, and a trend toward infection with antibiotic-resistant organisms was noted. Infections were a frequent complication of LVAD implantation. Further studies of interventions for preventing infection in LVAD recipients are warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981723     DOI: 10.1086/340052

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  What is the optimum antibiotic prophylaxis in patients undergoing implantation of a left ventricular assist device?

Authors:  Metesh Nalin Acharya; Robin Som; Steven Tsui
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-30

2.  Cardiovascular implantable device infections.

Authors:  George M Viola; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

Review 3.  Impact of adverse events on ventricular assist device outcomes.

Authors:  Aleksandar Adzic; Snehal R Patel; Simon Maybaum
Journal:  Curr Heart Fail Rep       Date:  2013-03

4.  Infectious Complications of Mechanical Circulatory Support (MCS) Devices.

Authors:  Stanley I Martin
Journal:  Curr Infect Dis Rep       Date:  2013-09-29       Impact factor: 3.725

5.  Left ventricular assist devices: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2004-03-01

6.  Prospective, multicenter study of ventricular assist device infections.

Authors:  Rachel J Gordon; Alan D Weinberg; Francis D Pagani; Mark S Slaughter; Pat S Pappas; Yoshifumi Naka; Daniel J Goldstein; Walter P Dembitsky; Julie C Giacalone; Jennifer Ferrante; Deborah D Ascheim; Alan J Moskowitz; Eric A Rose; Annetine C Gelijns; Franklin D Lowy
Journal:  Circulation       Date:  2013-01-11       Impact factor: 29.690

7.  Ventricular assist device infections.

Authors:  Denis Spelman; Donald Esmore
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

8.  Clinical manifestations and management of left ventricular assist device-associated infections.

Authors:  Juhsien Jodi C Nienaber; Shimon Kusne; Talha Riaz; Randall C Walker; Larry M Baddour; Alan J Wright; Soon J Park; Holenarasipur R Vikram; Michael R Keating; Francisco A Arabia; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2013-08-13       Impact factor: 9.079

9.  Renal replacement therapy in congestive heart failure requiring left ventricular assist device augmentation.

Authors:  Bernadette A Thomas; Christine M Logar; Arthur E Anderson
Journal:  Perit Dial Int       Date:  2012 Jul-Aug       Impact factor: 1.756

10.  Antithrombotic medication for cardioembolic stroke prevention.

Authors:  M Àngels Font; Jerzy Krupinski; Adrià Arboix
Journal:  Stroke Res Treat       Date:  2011-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.